Cargando…
Antibiotics and immunotherapy in gastrointestinal tumors: Friend or foe?
The incidence of gastrointestinal (GI) tumors is increasing year by year, and its pathogenesis is closely related to the intestinal flora. At present, the use of antibiotics is very common in the clinic. And cancer patients with low immunity are vulnerable to all sorts of infections, such as respira...
Autores principales: | Yan, Cong, Tu, Xiao-Xuan, Wu, Wei, Tong, Zhou, Liu, Lu-Lu, Zheng, Yi, Jiang, Wei-Qin, Zhao, Peng, Fang, Wei-Jia, Zhang, Hang-Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6580336/ https://www.ncbi.nlm.nih.gov/pubmed/31236389 http://dx.doi.org/10.12998/wjcc.v7.i11.1253 |
Ejemplares similares
-
De novo lipogenesis in metabolic homeostasis: More friend than foe?
por: Solinas, Giovanni, et al.
Publicado: (2015) -
Ferroptosis: friend or foe in cancer immunotherapy?
por: Demuynck, Robin, et al.
Publicado: (2023) -
Microbiota of the gastrointestinal tract: Friend or foe?
por: Senchukova, Marina A
Publicado: (2023) -
Therapy-Induced Tumor Cell Death: Friend or Foe of Immunotherapy?
por: van Schaik, Thijs A., et al.
Publicado: (2021) -
Tumor Temperature: Friend or Foe of Virus-Based Cancer Immunotherapy
por: Knapp, Jason P., et al.
Publicado: (2022)